CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 87 enrolled
Drug / intervention
DE-114 ophthalmic solution +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01363700
NCT01363700Phase 3Completed
CompareCT.gov

Double-masked, Comparison Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis - Phase 3, Confirmatory Study -

Santen Pharmaceutical Co., Ltd.·interventional·Posted Jun 1, 2011·Updated Nov 19, 2014

In Brief

A Phase 3 clinical trial evaluating DE-114 ophthalmic solution, Placebo ophthalmic solution, and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 87 participants across 1 site.

Detailed Summary

The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 1, 2011
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Posted 15.1 years ago

Interventions

DE-114 ophthalmic solutiondrug

Placebo ophthalmic solutiondrug

Olopatadine Hydrochloride 0.1% Ophthalmic Solutiondrug